SUNNYVALE, Calif., June 16, 2017 /PRNewswire/ -- In honor of
Father's Day, Accuray Incorporated
(NASDAQ: ARAY) joins Anova Cancer Care in recognizing the center's
commitment to providing the most advanced treatments available to
men with prostate cancer, many of whom are fathers. The center,
located in Lone Tree, Colorado,
has treated its 1,500th prostate cancer patient using the
CyberKnife® System—an advanced radiation therapy device designed to
deliver stereotactic body radiation therapy (SBRT). SBRT is a
highly precise form of radiation therapy which maximizes dose to
the tumor and minimizes dose to surrounding healthy tissue.
According to the American Cancer Society, more than 161,000 men
will be diagnosed with prostate cancer in 2017. It's important for
men to take action to improve their health, including learning
about medical conditions which specifically impact them, like
prostate cancer, and options for managing the disease. This
Father's Day, June 18, 2017, men
and their families can learn about prostate cancer at rallies held
by:
- ZERO – The End of Prostate Cancer
- The Prostate Health Education Network (PHEN)
The prostate gland can move unpredictably throughout the course
of treatment because of normal patient bodily functions – such as
filling of the bladder, gas in the bowel, or even patient movement
during the procedure – making the ability to track, detect and
correct for motion critically important. Unlike any other radiation
treatment, the CyberKnife System continually tracks and
automatically corrects the beam for movement of the prostate in
real-time throughout the entire treatment session. Published data
reinforce that CyberKnife prostate SBRT is effective, with minimal
side effects and impact on quality of life during and after
treatment, important considerations for men diagnosed with prostate
cancer.
Additional Information About CyberKnife Prostate SBRT
- Treatment with the CyberKnife System is non-invasive (no
surgery involved) and is completed in 4-5 treatment sessions, over
the course of one or two weeks. Conventional radiation therapy
typically requires 30-40 treatment sessions, over the course of
several weeks;
- CyberKnife treatment accuracy is achievable without the need
for invasive rectal balloons or spacers to spare the rectal
wall;
- The system can precisely target tumors and as a result, may
provide a safe radiation treatment option even for some previously
irradiated patients;
- SBRT increases patient satisfaction by reducing discomfort and
scheduling inconvenience versus conventional radiation
treatments.
Quotes
Tim B.: "When I was diagnosed with
prostate cancer I immediately imagined the worst. I have several
grandchildren who I want to spend time with as they grow up. I
discussed treatment options with my urologist and radiation
oncologist and together, we decided that treatment with the
CyberKnife® System was the best option for me. I liked that the
technology is really precise so the radiation would be targeting my
prostate and my risk for side effects would be minimized. And the
convenience of only needing five days of treatment was a real
bonus."
Lee K. McNeely, M.D.,
Radiation Oncologist at Anova Cancer Care: "Anova Cancer Care
is a busy radiation therapy center, so it's important that we have
technology we trust to provide our patients with the best possible
treatment option. We use the CyberKnife for prostate cancer because
it offers distinct advantages when treating this disease, most
notably it's the only system available with the ability to track
movement of the prostate and automatically adjust the radiation
beam during treatment. The CyberKnife System's accuracy is
sub-millimeter, enabling my colleagues and me to treat the disease
with unparalleled preservation of healthy tissue and provide
substantial quality of life and lifestyle benefits to
patients."
Stanley H. Galansky, MD, FACS,
FAAP, Urologist at Urology Associates: "Urology
Associates offers a range of treatment options for prostate cancer,
including the CyberKnife, which we administer on an out-patient
basis at Anova Cancer Care. We partnered with Anova to offer our
patients this option because we believe it effectively manages the
cancer with considerably fewer side effects than traditional cancer
treatments. With the CyberKnife System, we treat patients in 5
sessions and it's less expensive for the patient and their
insurance company. Most importantly, the system has provided
quality outcomes for our patients."
Joshua H. Levine, President
and Chief Executive Officer of Accuray: "We commend Dr. McNeely
and the Anova Cancer Care team on their dedication to improving the
lives of their patients. We appreciate our continued partnership
and are honored they have selected the CyberKnife technology to
treat so many of their low- to intermediate-risk prostate cancer
patients. The CyberKnife System is continuing to demonstrate its
position as the radiation treatment of choice for more and more
physicians and patients. It offers a convenient, non-invasive
approach which precisely targets the prostate cancer with minimal
disruption to patients' daily lives."
Important Safety Information
For Important Safety Information please refer
to http://www.accuray.com/safety-statement
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, and Accuray's
leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
+1 (781) 684-0770
accuray@MSLGROUP.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anova-marks-1500th-prostate-cancer-patient-treated-with-the-accuray-cyberknife-system-300475118.html
SOURCE Accuray Incorporated